{
    "Clinical Trial ID": "NCT00305448",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Fulvestrant 250 mg",
        "Fulvestrant 250 mg",
        "INTERVENTION 2: ",
        "  Fulvestrant 250 mg + Loading Dose",
        "  Fulvestrant 250 mg + Loading Dose"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor",
        "  Requiring hormonal treatment",
        "  Postmenopausal women defined as a woman who has stopped having menstrual periods",
        "Exclusion Criteria:",
        "  Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced breast cancer",
        "  Treatment with more than one previous regimen of endocrine therapy for advanced breast cancer",
        "  An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Objective Response Rate (ORR)",
        "  An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response.",
        "  Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization",
        "  Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)",
        "Results 1: ",
        "  Arm/Group Title: Fulvestrant 250 mg",
        "  Arm/Group Description: Fulvestrant 250 mg",
        "  Overall Number of Participants Analyzed: 45",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  11.1",
        "Results 2: ",
        "  Arm/Group Title: Fulvestrant 250 mg + Loading Dose",
        "  Arm/Group Description: Fulvestrant 250 mg + Loading Dose",
        "  Overall Number of Participants Analyzed: 51",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  17.6"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/45 (4.44%)",
        "  Cardiac Failure Congestive 0/45 (0.00%)",
        "  Diverticular Perforation 0/45 (0.00%)",
        "  Herpes Zoster 1/45 (2.22%)",
        "  Back Pain 0/45 (0.00%)",
        "  Fallopian Tube Cancer 0/45 (0.00%)",
        "  Fibroma 0/45 (0.00%)",
        "  Brain Stem Infarction 1/45 (2.22%)",
        "  Dizziness 0/45 (0.00%)",
        "  Optic Neuritis 0/45 (0.00%)",
        "Adverse Events 2:",
        "  Total: 5/51 (9.80%)",
        "  Cardiac Failure Congestive 1/51 (1.96%)",
        "  Diverticular Perforation 1/51 (1.96%)",
        "  Herpes Zoster 0/51 (0.00%)",
        "  Back Pain 1/51 (1.96%)",
        "  Fallopian Tube Cancer 1/51 (1.96%)",
        "  Fibroma 1/51 (1.96%)",
        "  Brain Stem Infarction 0/51 (0.00%)",
        "  Dizziness 0/51 (0.00%)",
        "  Optic Neuritis 1/51 (1.96%)"
    ]
}